Evaluating clinically meaningful change on the ITP-PAQ: Preliminary estimates of minimal important differences

Current Medical Research and Opinion

Volumn 25, Issue 2, 2009, Pages 375-383

  Mathias, Susan D ^a   Gao, Sue K ^b   Rutstein, Mark ^b   Snyder, Claire F ^c   Wu, Albert W ^c   Cella, David ^d  

^a Health Outcomes Solutions   (United States)

^b AMGEN INC   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Health related quality of life; Immune thrombocytopenic purpura; ITP PAQ; Minimal important differences; Questionnaire

Indexed keywords

PLACEBO; ROMIPLOSTIM;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EFFECT SIZE; EUROPE; EVALUATION; FEMALE; FERTILITY; GLOBAL CHANGE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ERROR; MULTICENTER STUDY; PATIENT ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHYSICIAN; PREMENSTRUAL SYNDROME; PSYCHOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SOCIAL BEHAVIOR; SYMPTOM; UNITED STATES; AGED; MIDDLE AGED; PATHOPHYSIOLOGY; QUALITY OF LIFE;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 64249130237     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802634119     Document Type: Article

References (21)

1. Schunemann HJ, Akl EA, Guyatt GH. Interpreting the results of patient reported outcome measures in clinical trials: the clinician's perspective. Health Qual Life Outcomes 2006;4:62 (Pubitemid 44613276)
2. Yost KJ, Sorensen MV, Hahn EA, et al. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health 2005;8:117-127 (Pubitemid 40525373)
3. Brozek JL, Guyatt GH, Schunemann HJ. How a well-grounded minimal important difference can enhance transparency of labeling claims and improve interpretation of a patient reported outcome measure. Health Qual Life Outcomes 2006;4:69 (Pubitemid 44649668)
4. Revicki DA, Cella D, Hays RD, et al. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006;4:70 (Pubitemid 44649667)
5. Jaeschke R, Singer J, Guyatt GH. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10: 407-415
6. Wyrwich KW, Bullinger M, Aaronson N, et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005;14:285-295 (Pubitemid 40576381)
7. Sloan JA. Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions. Int J Chron Obstruct Pulmon Dis 2005;2:57-62 (Pubitemid 40776224)
8. US FDA. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4:79
9. Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008;61:102-109
10. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997;126:307-314 (Pubitemid 27078779)
11. Snyder CF, Mathias SD, Cella D, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin 2008; 24:2767-2776
12. George JN. Diagnosis, clinical course, and management of idiopathic thrombocytopenic purpura. Curr Opin Hematol 1996;3: 335-340 (Pubitemid 26404688)
13. McMillan R, Bussel JB, George JN, et al. Self-reported health-related quality of life in adults with immune thrombocytopenic purpura. Am J Hematol 2008;83:150-154
14. Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007;5:11 (Pubitemid 46359491)
15. Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther 2007;29:950-962 (Pubitemid 47223425)
16. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371: 395-403 (Pubitemid 351181334)
17. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988
18. Khanna D, Furst DE, Wong W, et al. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res 2006;16:1083-1092
19. Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol 2004;57:1153-1160 (Pubitemid 39573022)
20. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific questionnaire. J Clin Epidemiol 1994;47:81-87 (Pubitemid 24034293)
21. Nunnally JC, Bernstein IH. Psychometric Theory, 3rd edn. New York, NY: McGraw-Hill, 1994